Sufficient financial resources to conduct research and development activities especially in clinical development are crucial for small and medium sized biotech enterprises. In times where pharmaceutical corporations seek more and more often to fill their pipelines with drug candidates from biotech, new forms of collaboration have emerged. Corporate venturing, co-investment, innovation centers or collaborators are some of the cooperation routes taken. What are the benefits and drawbacks – if any? How is business development for the pharmaceutical industry changing? What will future cooperation between pharma and biotech look like?

Moderator:

Siegfried Bialojan
Head Life Science Center
Ernst & Young

Panelists:

• Jan Adams, EMBL Ventures
• Alethia de Leon, BaseLaunch
• Lubor Gaal, Almirall
• Markus Kostka, Boehringer Ingelheim
• Thilo Schroeder, Nextech Invest